What should be considered for patients with allergies who are undergoing treatment for persistent severe asthma?

Omalizumab is a monoclonal antibody that specifically targets IgE, which plays a significant role in the allergic response. For patients with allergies who are experiencing persistent severe asthma, omalizumab can be an effective treatment option because it reduces the overall allergic inflammation and subsequent asthma symptoms. This is particularly useful for individuals whose asthma is exacerbated by specific allergens, as it can help manage both their asthma and allergy symptoms more effectively.

In addition, omalizumab is administered as an injection and can be used alongside other asthma medications, making it a versatile choice for those with severe asthma who also have allergic triggers. Its ability to decrease the frequency and severity of asthma attacks can improve overall control of the condition.

Other options, such as theophylline, cromolyn, and nedocromil, are treatments with different mechanisms of action. Theophylline, for instance, is a bronchodilator, while cromolyn and nedocromil act as anti-inflammatory medications but are not specifically targeted toward allergic responses as effectively as omalizumab. Thus, omalizumab stands out as the most appropriate choice for managing severe asthma in patients with underlying allergies.